Cell Therapy Manufacturing Market to be Driven by the Development in Healthcare Infrastructure of United Kingdom Through 2028
Growing regulatory approval for new
products and rapid technological advancements in cell therapies are the major
drivers for the United Kingdom cell therapy manufacturing market.
According
to TechSci Research report, “United Kingdom Cell
Therapy Manufacturing Market – By Region, Competition, Forecast and
Opportunities, 2028,” the United Kingdom cell therapy manufacturing market is
anticipated to register a high CAGR during the forecast period. This can be
ascribed to growth in geriatric population of United Kingdom along with
prevalence of severe diseases which require cell-based therapies for their
treatment.
United Kingdom have emerged as leading country for
cell therapy treatments owing to their innovations in treatment choices for
patients. The United Kingdom’s National Health Service Blood and Transplant
(NHSBT), which manages blood and platelet donations, organ, stem cell and
tissue transplants in the country, opened a new clinical biotech center to help
boost the U.K.’s capacity to make DNA plasmids and viral vectors. The company
will manufacture products for the development of potential curative therapies
for currently incurable diseases such as certain cancers, sickle cell anemia
and cystic fibrosis. Moreover, availability of more than 700 consultant
hematologists practicing in United Kingdom along establishment of new Contract
Development and Manufacturing Organizations (CDMOs) in the country are
anticipated to propel the growth of United Kingdom cell therapy manufacturing
market in the forecast period. United Kingdom is the third leading cluster of
cell and gene therapy production across the world. As per 2021, there are
around 168 ongoing clinical trials taking place in the country for cell therapy
which makes around 9% of global trials. Growing regulatory approval for new
products in the country is another significant factor which is expected to
drive the growth of cell therapy manufacturing market in United Kingdom. For instance,
in 2018, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) received
approval from European Medicines Agency (EMA). Kymriah is a CAR T-cell therapy
developed by Novartis to treat certain types of high-grade B-cell lymphoma and
acute lymphoblastic leukemia in children and young adults. Yescarta is approved
for adult patients with relapsed or refractory DLBCL or primary mediastinal
large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.
Rapid technological advancements associated with growth of cell-based therapies
are also expected to register a lucrative growth to United Kingdom cell therapy
manufacturing market in the futuristic period. CRISPR/Cas9 is a gene-editing
tool which has revolutionized biomedical research in recent years. CRISPR/Cas9
edits genes by precisely cutting DNA and allowing natural DNA repair processes
to take over.
This technology holds great potential
for treating genetic disorders and developing personalized cell therapies.
Moreover, chimeric antigen receptor T-cell (CAR-T) therapies have shown
remarkable success in treating certain types of cancer. In this approach, a
patient's T cells are engineered to express receptors that target cancer cells,
enhancing the immune system's ability to recognize and destroy cancer cells.
CAR-T therapies are also approved for treatment of leukemia and lymphoma.
Growth in geriatric population of United Kingdom along with emergence of
age-related disorder such as osteoarthritis is also attributed to drive the
growth of United Kingdom cell therapy manufacturing market in the forecast
period. Mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP) therapy,
and gene therapy are some of the common cell-based therapies used to cure
osteoarthritis. For instance, in MSC therapy, stem cells are harvested from the
patient's own body (autologous) or from a donor (allogeneic), and then injected
into the affected joint. This promotes the tissue repair and modulate the
immune response potentially relieving the joint pain.
However, significant operational costs related with
manufacturing of allogenic cell therapies and risks accompanied with acceptance
of cell-based therapies are expected to slow down the growth of the market in
the coming years.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" United Kingdom Cell Therapy
Manufacturing Market.”
The United Kingdom cell therapy manufacturing market
segmentation is based on therapy, source of cell, scale of operation, source,
application, end user, company, and region.
Based on application, the market is further divided
into oncology, cardiovascular diseases, orthopedic diseases, and others. Oncology
segment is likely to dominate the market in the forecast period. This
can be ascribed to rise in prevalence of cancer and growing adoption of novel
treatment models for targeted therapy.
Some
of the major companies operating in the United Kingdom cell
therapy manufacturing market include:
- Novartis Pharmaceuticals UK Ltd.
- Gilead
Sciences, Ltd.
- Thermo
Fisher Scientific Inc.
- Catalent,
Inc.
- Oxford
Biomedica plc.
- Amgen
Limited
- Takeda
Pharmaceutical Company Limited
Download
Free Sample Report
Customers can also request for 10% free
customization on this report.
“Certain regions are expected to
dominate the demand for cell therapy manufacturing in United Kingdom. Presence
of excelled pharmaceuticals and biotech industries in United Kingdom which are
dedicated to improve the future of cell-based therapies by receiving approval
from U.S. Food and Drug Administration (FDA) every year on their multiple novel
methodologies are expected to register an impressive growth to United Kingdom cell
therapy manufacturing market in the forecast period," said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based global
management consulting firm.
United Kingdom Cell Therapy Manufacturing Market – Industry Size, Share, Trends, Competition,
Opportunity, and Forecast, 2018-2028F Segmented By End User (Pharmaceutical
& Biotechnology Companies, Academic & Research Institutes, and Others),
By Region and Competition”,
has evaluated the future growth potential of United Kingdom cell therapy
manufacturing market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in United Kingdom cell therapy manufacturing
market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com